Related references
Note: Only part of the references are listed.Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours
Reda Stankunaite et al.
EUROPEAN JOURNAL OF CANCER (2022)
Liquid Biopsy: From Discovery to Clinical Application
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2021)
Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Manuela Krumbholz et al.
CLINICAL CANCER RESEARCH (2021)
Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease
Nathalie S. M. Lak et al.
CLINICAL CANCER RESEARCH (2021)
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium
Jack F. Shern et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder et al.
NATURE COMMUNICATIONS (2021)
An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy
Gianni Bisogno et al.
PEDIATRIC BLOOD & CANCER (2020)
The Emerging Role of Ras Pathway Signaling in Pediatric Cancer
Gina M. Ney et al.
CANCER RESEARCH (2020)
Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing
Lauren Mc Connell et al.
CANCERS (2020)
Circulating tumor DNA and liquid biopsy in oncology
David W. Cescon et al.
NATURE CANCER (2020)
Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma
Norio Nakagawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
Gianni Bisogno et al.
LANCET ONCOLOGY (2019)
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma A report from the Children's Oncology Group
Suman Malempati et al.
CANCER (2019)
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies
Samuel D. Abbou et al.
PEDIATRIC BLOOD & CANCER (2019)
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group
David S. Shulman et al.
BRITISH JOURNAL OF CANCER (2018)
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Douglas S. Hawkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma
Mathieu Chicard et al.
CLINICAL CANCER RESEARCH (2018)
Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group
Erin R. Rudzinski et al.
PEDIATRIC BLOOD & CANCER (2017)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Brenda J. Weigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
Jack F. Shern et al.
CANCER DISCOVERY (2014)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
Samuel Q. Li et al.
PLOS ONE (2013)
Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 Study
Odile Oberlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Circulating Tumor Cells Bad News in Breast Cancer
C. Bettegowda
Science Translational Medicine (2012)
Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
R. Beverly Raney et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803
Carola A. S. Arndt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Concomitant amplification and expression of PAX7-FKHR and MYCN in a human rhabdomyosarcoma cell line carrying a cryptic t(1;13)(p36;q14)
E Frascella et al.
CANCER GENETICS AND CYTOGENETICS (2000)